一分钟看懂
这是一项关于白血病的III 期研究，登记的药物或干预包括Bleximenib；Venetoclax (VEN)；Azacitidine (AZA)；Placebo，当前状态为招募中。登记地点显示中国北京、长春、成都、重庆等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Bleximenib；Venetoclax (VEN)；Azacitidine (AZA)；Placebo · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记摘要未单独列出可展示的排除条件，请查看英文原文并向研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University First Hospital · 北京
- Peking University People's Hospital · 北京
- Peking University Third Hospital · 北京
- The first Affiliated Hospital of Jilin University · 长春
- Sichuan Provincial Peoples Hospital · 成都
- West China Hospital Si Chuan University · 成都
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- Sun Yat Sen University Cancer Center · 广州
- The First Affiliated Hospital Zhejiang University College of Medicine · 杭州
- The First Affiliated Hospital of USTC Anhui Provincial Hospital · 合肥
- Qilu Hospital of Shandong University · 济南
- The Second Hospital & Clinical Medical School Lanzhou University · 兰州
- The First Affiliated Hospital of NanChang University · 南昌
- Zhongda Hospital Southeast University · 南京
- The First Affiliated Hospital of Guangxi Medical University · 南宁
- Shengjing Hospital Of China Medical University · 沈阳
- The Second People's Hospital of Shenzhen · 深圳
- First Affiliated Hospital SooChow University · 苏州
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences · Tijian
- The First Affiliated Hospital of Wenzhou Medical University · 温州
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology · 武汉
- TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology · 武汉
- The Second Affiliated Hospital of Xi'an Jiaotong University · 西安
- The first affiliated hospital of xiamen university · 厦门
- Henan Cancer Hospital · 郑州
公开的入选条件
- Inclusion criteria:
- * Be 18 years of age or older at the time of informed consent
- * Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (\> or =) 10% bone marrow blasts per 2022 international Consensus Classification cr
- * Ineligible for intensive chemotherapy based on the following criteria: a) \>= 75 years of age and ineligible per physician's discretion, with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, b) \>=18 to \<75 years of age with \>= 1 of the
- * Participants must have adequate hepatic and renal function
- * A female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment
- * A male participant must agree to use protocol-specified contraception while enrolled in this study for at least 90 days after the last dose of study treatment
- * Must sign an informed consent form indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06852222；登记信息更新于 2026-09-25。